Johnson & Johnson Completes Acquisition of Halda Therapeutics for $3.05 Billion

Merck to Acquire Harpoon Therapeutics for $680M

January 8, 2024

Biotechnology

Merck has agreed to acquire clinical-stage immunotherapy company Harpoon Therapeutics for $23.00 per share in cash, representing an approximate total equity value of $680 million. The acquisition gives Merck access to Harpoon's TriTAC / ProTriTAC platforms and lead candidate HPN328 (a DLL3-targeting T‑cell engager) to enhance its oncology pipeline; the deal is expected to close in the first half of 2024, subject to customary conditions.

Johnson & Johnson Acquires Intra-Cellular Therapies

April 2, 2025

Healthcare Services

Johnson & Johnson has acquired Intra-Cellular Therapies, paying $132 per share in cash for all outstanding shares, for an equity value of approximately $14.6 billion. The deal adds CAPLYTA (lumateperone) and a clinical-stage pipeline, including ITI-1284, to strengthen J&J’s neuroscience portfolio.

Johnson & Johnson to Acquire Ambrx Biopharma in ~$2 Billion All-Cash Deal

January 8, 2024

Pharmaceuticals

Johnson & Johnson announced it has entered into a definitive agreement to acquire Ambrx Biopharma in an all-cash merger transaction valued at about $2 billion (about $1.9 billion net of estimated cash acquired). The deal is intended to add Ambrx’s proprietary synthetic biology and ADC (antibody-drug conjugate) technology platform and its clinical and preclinical oncology pipeline to J&J’s targeted oncology therapeutics efforts.

Takeda Pharmaceutical to Acquire GammaDelta Therapeutics

October 27, 2021

Biotechnology

Takeda exercised its option to acquire GammaDelta Therapeutics Limited, gaining its allogeneic gamma-delta (γδ) T cell therapy platforms and early-stage cell therapy programs. The acquisition is expected to be finalized in Q1 of Takeda’s fiscal year 2022, subject to antitrust review (including HSR).

Huma Therapeutics Acquires Alcedis GmbH

January 9, 2023

Healthcare Services

Huma Therapeutics Limited has acquired Alcedis GmbH, a German clinical research and technology firm with more than 25 years of experience. The deal combines Huma's digital health and decentralized clinical trial platform with Alcedis' operational clinical trial expertise to create an expanded end-to-end digital clinical trials capability; financial terms were not disclosed.

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.